Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
GamaMabs Pharma
Toulouse, Occitanie, Francegamamabs.com ↗
- Ownership
- Private
- Employees
- ~7
- Development stage
- Other
01
Overview
GamaMabs developed first-in-class monoclonal antibodies targeting AMHR2 for oncology indications. Its lead asset murlentamab was well tolerated in Phase 1/2 trials but showed only modest single-agent efficacy and was discontinued in early 2021. The company’s AMHR2 franchise—including drug product and manufacturing cell lines—was acquired by Exelixis in May 2021. Preclinical data supported the potential of AMHR2 as a novel target for solid tumors
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodyAntibody-drug conjugate (ADC)Biologic (for low-fucose EMABling® antibodies)
- Industry
- Biotech
02
Partnerships
MedImmune/AstraZeneca [licensing agreement for ADC technology/PBD toxin linker technology]LFB Biotechnologies [licensed EMABling® platform technology]
Beyond the preview
Go deeper on GamaMabs Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GamaMabs Pharma.